GlassScriptPhysician profile
Leslie Sweere
NPI 1902211907
$1,785.81
in general payments reported to CMS, 2019-2025
11 companies · $419 in 2025
The $419 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $338 · 2023: $768 · 2024: $260 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,086.37 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.74 | 2023-2025 | Caplyta |
| Abbvie INC. | $97.43 | 2025 | |
| Emd Serono, INC. | $94.75 | 2023-2025 | Serostim |
| Bausch Health US, LLC | $76.07 | 2022-2023 | Aplenzin |
| Lilly USA, LLC | $46.64 | 2023 | Mounjaro |
| Tris Pharma INC | $36.72 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $28.92 | 2025 | Pifeltro |
| Janssen Biotech, INC. | $19.13 | 2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $18.75 | 2023 | Trintellix |
| Boston Scientific Corporation | $18.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Sweere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.